Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea

Trial Profile

Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Brimonidine (Primary) ; Ivermectin (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Acronyms MOSAIC
  • Sponsors Galderma
  • Most Recent Events

    • 11 Sep 2017 Results from this trial have been published in the Journal of Drugs in Dermatology, according to a Galderma media release.
    • 13 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top